Fair Lawn, New Jersey Clinical Trials

A listing of Fair Lawn, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

recurrent endometrial cancer
endometrial cancer
cancer therapy
paclitaxel
cancer
Research Site
 (3.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +94 other locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the …

stage iiia lung cancer ajcc v7
gemcitabine
stage ii lung cancer ajcc v7
stage iia lung squamous cell carcinoma ajcc v7
non-small cell carcinoma
Neurosurgeons of New Jersey-Ridgewood
 (3.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +358 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
antihemophilic factor
factor ix
hemophilia
fitusiran
Investigational Site Number 8400008
 (4.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

hepatitis b surface antigen
hbv dna
dexamethasone
arginine hydrochloride
antibiotic therapy
Investigational Site Number 8400006
 (4.8 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
antihemophilic factor
factor ix
hemophilia
fitusiran
Investigational Site Number 8400008
 (4.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

carboplatin
metastasis
adjuvant therapy
stage iv non-small cell lung cancer
NTRK
New Jersey Cancer Care and Blood Disorders (NJCCBD)
 (9.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +27 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

small cell lung cancer
growth factor
lymphoma
cancer
stage iv non-small cell lung cancer
Hackensack Univ Med Ctr /ID# 216484
 (4.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs

The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find …

sarcoma of the extremity
soft tissue sarcoma
serum pregnancy test
sarcoma
primary tumor
Memorial Sloan Kettering Bergen (All protocol activities)
 (9.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.

systemic therapy
oophorectomy
metastasis
measurable disease
bilateral oophorectomy
John Theurer Cancer Center at Hackensack University Medical Center
 (4.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for …

Memorial Sloan Kettering Bergen (Limited Protocol Activities)
 (9.1 away) Contact site
  • 0 views
  • 02 Dec, 2024
  • +6 other locations